US Pharma MarketingAxoltis says its Phase 2 study for an experimental ALS drug failed
French biotech Axoltis reported Phase 2 failure for NX210c in ALS, missing primary endpoint but showing secondary signals, including 51% slower progression vs placebo. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
The French biotech Axoltis Pharma reported a Phase 2 failure in ALS on Tuesday morning, but suggested it found a small signal to move the drug forward amid a noisy dataset.
Researchers were testing whether ...
Source: Endpoints News